• Corporate
• Markets
• Info-Tech
• Marketing
• Money & Banking
• Agri-Biz & Commodities
• Industry & Economy
• Logistics
• Government
• Opinion
• Variety
• Columns
• States
• Web Extras
• Index

• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

• Rates

• Ports

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Subscription

• Business Line

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

NEW DELHI: Over 1.7 billion people, mostly concentrated in India and Africa, do not have access to essential drugs and the situation is worsening with the dwindling public healthcare spending in the developing countries.

“More than 1.7 billion people in India and Africa do not have access to essential drugs... across the world, about 14 million people die due to infectious diseases and 10 million children die due to vaccine preventable diseases,'' K Satyanarayana, Head o f the Intellectual Property Rights Unit, Indian Council of Medical Research (ICMR) told PTI.

However, India has one of the best drug procurement systems in the world especially in states like Tamil Nadu and Delhi, Satyanarayana said quoting a WTO report. “These should be replicated in other states as well,'' he said. The pharma industry, he sai d, should play vital role in making healthcare affordable.

“The pharma industries can form strategic partnership with the government to bring out drugs which poor people can afford.'' “For chronic diseases, there are reports of the industry willing to consider dual pricing so that poor people can access drugs f or cancer, diabetes, cardiovascular diseases etc,'' he said.

Satyanarayana said the Indian Patent Office should not hesitate to invoke provisions of compulsory licensing and flexibilities available under TRIPS and India Patent Act whenever the drugs required by poor remain out of reach. - PTI

Prev: Aurobindo gets FDA nod for AIDS drug
Next: FMC asked to act fast in delivery defaults issue

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line